Table 3.
Patient and tumor characteristics compering to EORTC and other group results
| Study Group No. (%) | EORTC Group No. (%) [7] | CUETO Group No. (%) [19] | UK Group No. (%) [21] | |
|---|---|---|---|---|
| Total number of patients | 91 | 2596 | 1062 | 109 |
| Age | ||||
| <60 | 33 (36.3) | 859 (33.1) | 331 (33.2) | 29 (26.6) |
| 61–70 | 20 (22.0) | 890 (34.3) | 394 (37.1) | 35 (32.1) |
| 71–80 | 25 (27.5) | 690 (26.6) | 301 (28.3) | 31 (28.4) |
| >80 | 13 (14.2) | 118 (4.5) | 36 (3.4) | 13 (11.9) |
| unknown | 39 (1.5) | 1 (0.9) | ||
| Gender | ||||
| Male | 83 (91.2) | 2044 (78.7) | – | 84 (77.1) |
| Female | 8 (8.8) | 561 (19.8) | – | 25 (22.9) |
| Number of tumors | ||||
| single | 64 (71.4) | 1465 (56.4) | 535 (50.4) | 64 (58.7) |
| 2 up to 7 | 25 (27.5) | 836 (32.2) | 438 (41.3) | 32 (29.3) |
| more than 8 | 1 (1.1) | 255 (9.8) | 89 (8.4) | 13 (11.9) |
| Size of tumors | ||||
| < 3 cm | 59 (64.9) | 2087 (80.4) | 581 (57.4) | 64( 58.6) |
| > 3 cm | 32 (35.1) | 464 (17.9) | 481 (45.3) | 43 (39.4) |
| PT category | ||||
| Ta | 60 (65.9) | 1451 (55.9) | 214 (20.2) | 78 (71.5) |
| T1 | 31 (34.1) | 1108 (42.7) | 848 (79.8) | 31 (28.5) |
| Presence of CIS | ||||
| No | 87 (95.6) | 2440 (94.0) | 982 (92.5) | 100 (91.7) |
| Yes | 4 (4.4) | 113 (4.4) | 80 (7.5) | 9 (8.3) |
| Grade of tumor | ||||
| G1 | 49 (53.8) | 1121 (43.2) | 167 (15.7) | 98 (89.9) |
| G2 | 25 (27.5) | 1139 (43.9) | 629 (59.2) | |
| G3 | 17 (18.7) | 271 (10.4) | 266 (25) | 11 (10.1) |
| Follow–up | ||||
| median | 2.8 | 3.9 | – | 5 |
| maximum | 3.8 | 14.8 | – | 5 |
| Recurrence | ||||
| No | 68 (74.7) | 1356 (52.2) | 706 (66.5) | 40 (36.7) |
| Yes | 23 (25.3) | 1240 (47.8) | 356 (33.5) | 69 (63.3) |
| Progression | ||||
| No | 80 (87.9) | 2317 (89.3) | – | 95 (87.2) |
| Yes | 11 (12.1) | 279 (10.7) | – | 14 (12.8) |
| Survival | ||||
| Alive | 84 (89.0) | 1743 (67.1) | – | 98 (90) |
| Dead | 10 (11.0) | 279 (32.9) | – | 11 (10) |